US 12,110,551 B2
Combination of biomarkers for detecting and evaluating a hepatic fibrosis
Bénédicte Watelet, Saint-Clément-de-Rivière (FR); Tarik Asselah, Paris (FR); Ivan Bieche, Suresnes (FR); Isabelle Catherine Batxelli, Aigues-Vives (FR); Nathalie Jullian, Montrouge (FR); Michel Vidaud, Fontenay-sous-Bois (FR); Patrick Marcellin, Paris (FR); Daniel Laune, Grabels (FR); Mohammad Afshar, Paris (FR); and Eve Mathieu Dupas, Montpellier (FR)
Assigned to BIO-RAD EUROPE GMBH, Basel (CH); ARIANA PHARMACEUTICALS, Paris (FR); INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, Paris (FR); ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS, Paris (FR); and CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris (FR)
Filed by BIO-RAD EUROPE GMBH, Basel (CH); ARIANA PHARMACEUTICALS, Paris (FR); INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, Paris (FR); ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, Paris (FR); and CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris (FR)
Filed on Dec. 28, 2021, as Appl. No. 17/563,107.
Application 15/488,614 is a division of application No. 13/984,702, granted, now 9,624,541, previously published as PCT/EP2012/052234, filed on Feb. 9, 2012.
Application 17/563,107 is a continuation of application No. 16/553,213, filed on Aug. 28, 2019, abandoned.
Application 16/553,213 is a continuation of application No. 15/488,614, filed on Apr. 17, 2017, granted, now 10,435,744.
Claims priority of provisional application 61/440,986, filed on Feb. 9, 2011.
Claims priority of application No. 1151022 (FR), filed on Feb. 9, 2011.
Prior Publication US 2022/0205039 A1, Jun. 30, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/68 (2018.01); C12Q 1/6876 (2018.01); C12Q 1/6883 (2018.01); G01N 33/576 (2006.01); C12Q 1/70 (2006.01)
CPC C12Q 1/6876 (2013.01) [C12Q 1/6883 (2013.01); G01N 33/576 (2013.01); C12Q 1/706 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/158 (2013.01); G01N 2800/085 (2013.01); G01N 2800/60 (2013.01); G01N 2800/7052 (2013.01)] 8 Claims
 
1. A kit comprising reagents attached to a solid support that specifically detect A2M, MMP7, and TIMP1, wherein said reagents are nucleic acids that hybridize specifically to RNA transcribed from A2M, MMP7, and TIMP1 and/or to the cDNA obtained by reverse transcription of said RNAs, or are proteins, polypeptides or peptides that specifically bind to the proteins encoded by A2M, MMP7, and TIMP1.